High Risk Neuroblastoma — Trials

High Risk Neuroblastoma — Trials · CancerIndex

Clinical trials

Registered studies

18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 9%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06607692	Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED)	recruiting	Phase 1 / Phase 2	25	Fundación de investigación HMOTHER	1	Jun 4, 2026	clinicaltrials
NCT07502287	Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma(DUAL-NK-NB)	recruiting	Phase 1 / Phase 2	36	Beijing BiotechINDUSTRY